{'fraction_non_alphanumeric': 0.028896672504378284, 'fraction_numerical': 0.013134851138353765, 'mean_word_length': 5.927272727272728, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Androgen receptor targeting drugs in castration‐resistant prostate cancer and mechanisms of resistance

Reactivated androgen receptor (AR) signaling drives castration‐resistant prostate cancer (CRPC). The novel AR targeting drugs abiraterone and enzalutamide have improved survival of CRPC patients. However, resistance to these agents develops and patients ultimately succumb to CRPC. Potential mechanisms of resistance include the following: 1) Expression of AR splice variants, such as the AR‐V7 isoform, which lacks the ligand‐binding domain; 2) AR missense mutations in the ligand‐binding domain, such as F876L and T877A; and 3) Mutation or overexpression of androgen biosynthetic enzymes or glucocorticoid receptor. Several novel agents may overcome resistance mechanisms. Galeterone acts through multiple mechanisms that include degradation of AR protein and is being evaluated in CRPC patients positive for AR‐V7. EPI‐001 and related compounds inhibit AR splice variants by targeting the N‐terminal transactivation domain of AR. Promising therapies and novel biomarkers, such as AR‐V7, may lead to improved outcomes for CRPC patients.